Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
103.26 USD   +0.62%
09/29Ascendis Pharma Added to Wedbush Best Ideas List
MT
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ascendis Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

08/10/2022 | 04:01pm EDT

Ascendis Pharma A/S reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was EUR 6.16 million compared to EUR 1.02 million a year ago. Net loss was EUR 81.32 million compared to EUR 134.37 million a year ago. Basic loss per share from continuing operations was EUR 1.46 compared to EUR 2.5 a year ago.
For the six months, sales was EUR 12.99 million compared to EUR 1.77 million a year ago. Net loss was EUR 206.82 million compared to EUR 197.17 million a year ago. Basic loss per share from continuing operations was EUR 3.68 compared to EUR 3.66 a year ago.


ę S&P Capital IQ 2022
All news about ASCENDIS PHARMA A/S
09/29Ascendis Pharma Added to Wedbush Best Ideas List
MT
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweigh..
MT
09/14Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
09/13Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 20th Annual Globa..
CI
09/12Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directo..
CI
09/12New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Phar..
AQ
09/12Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial
CI
09/08European ADRs Move Slightly Higher in Thursday Trading
MT
09/07Transcript : Ascendis Pharma A/S Presents at Citi's 17th Annual BioPharma Con..
CI
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 34,8 M 34,1 M 34,1 M
Net income 2022 -500 M -490 M -490 M
Net cash 2022 620 M 608 M 608 M
P/E ratio 2022 -11,7x
Yield 2022 -
Capitalization 5 882 M 5 768 M 5 768 M
EV / Sales 2022 151x
EV / Sales 2023 40,9x
Nbr of Employees 639
Free-Float 10,3%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 105,30 €
Average target price 146,14 €
Spread / Average Target 38,8%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-23.24%5 768
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 044